Who misses out without subsidy
9:45–10:13 · 28s
Priya quantifies the cost burden of tirzepatide and estimates 450,000 Australians with type 2 diabetes could miss out, sparking a debate on alternatives and access.
9:45–10:13 · 28s
Priya quantifies the cost burden of tirzepatide and estimates 450,000 Australians with type 2 diabetes could miss out, sparking a debate on alternatives and access.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.